THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

CURRICULUM VITAE

Ben C Valdez, Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Associate Professor, Baylor College of Medicine, Houston, TX

CITIZENSHIP

United States
Philippines

EDUCATION

Degree-Granting Education

University of the Philippines, Los Banos, Laguna, Philippines, BS, Cum Laude, 1979, Applied Chemistry

Lousiana State University, Baton Rouge, LA, PHD, 1988, Biochemistry

Postgraduate Training

Postgraduate Training, Baylor College of Medicine, Houston, TX, Instructor, 1/1989-1/1994

CREDENTIALS

Board Certification

N/A

Licensures

Active

N/A

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Instructor, Department of Chemistry, University of the Philippines, Los Banos, Laguna, Philippines, 6/1979-12/1982

Graduate Assistant, Department of Biochemistry and Molecular Biology, Louisiana State University, Baton Rouge, LA, 1/1983-12/1988

Instructor, Pharmacology, Baylor College of Medicine, Houston, TX, 1/1989-1/1994

Assistant Professor, Pharmacology, Baylor College of Medicine, Houston, TX, 1/1995-5/2005

Assistant Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2005-8/2011

Adjunct Associate Professor, Baylor College of Medicine, Houston, TX, 5/2005-present

Associate Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

N/A

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

N/A

HONORS AND AWARDS

Ambassador Benedicto Medal of Excellence in Sugar Technology, University of the Philippines, 1979

Graduated cum laude, University of the Philippines, 1979

Joaquin Gonzales Medal of Excellence, University of the Philippines, 1979

The Annual Robert Scott and Louise Pierce Allen Award, Louisiana State University, 1988

The National Institutes of Health Shannon Award, NIH, 1995

RESEARCH

Grants and Contracts

Funded

Research Scientist, 25%, The Therapy of CML, P01 CA049639, NIH/NCI, PI - Champlin, 2/12/1997-2/28/2016 ($312,000/year)

Co-Investigator, 25%, A randomized study of once daily Fludarabne-Clofarabine vs Fludarabine alone combined with IV Busulfan follwoed by allogeneic hemopoietic stem cell transplantation for AML and MDS, CS2012-0036506LG 01, Otsuka Pharmaceutical Development & Commercialization, Inc., PI - Champlin, 2/1/2012-3/31/2014 ($625,000/year)

Pending

N/A

Other

N/A

Completed

N/A

Not Funded

N/A

Protocols

Funded

N/A

Unfunded

N/A

Patents and Technology Licenses

Patents

Platform Brightworks Two, LTD, Borje S. Andersson, Jeffrey Tarrand, Benigno Valdez. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same, 2651450, 12/16/2011-12/16/2031, Issued

Platform Brightworks Two, LTD, Borje S. Andersson, Benigno C. Valdez, Jeffrey Tarrand. Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same, United States, US 13/452,033, 7/14/2016, Issued

Platform Brightworks Two, Ltd., Andersson, Borje S.; Tarrand, Jeffrey and Valdez, Benigno C.. Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds, Australia, 20113435676, 12/22/2016-12/16/2036, Issued

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Research Competitiveness Subprogram (RCS) of the Louisiana Board of Regents Support Fund Research and Development Program, Research Competitiveness Subprogram, Reviewer, 1999-2002

Ad hoc scientific reviewer for research grants, Research Grants, Ad hoc scientific reviewer, National Science Foundation, 2002

DOD USAMRMC-CDMRP Breast Cancer Research Program (Cell Biology-2 Study Section), DOD, Scientific Reviewer, 2002-2004

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. French BA, **Valdez BC**, Younathan ES, Chang SH. High-level expression of Bacillus stearothermophilus 6-phosphofructo-1-kinase in Escherichia coli. Gene 59(2-3):279-83, 1987. PMID: 2963782.
2. **Valdez BC**, Chang SH, Younathan ES. Site-directed mutagenesis at the regulatory site of fructose 6-phosphate-1-kinase from Bacillus stearothermophilus. Biochem Biophys Res Commun 156(1):537-42, 10/1988. PMID: 2972287.
3. **Valdez BC**, French BA, Younathan ES, Chang SH. Site-directed mutagenesis in Bacillus stearothermophilus fructose-6-phosphate 1-kinase. Mutation at the substrate-binding site affects allosteric behavior. J Biol Chem 264(1):131-5, 1/1989. PMID: 2521215.
4. **Valdez BC**, Chen Z, Sosa MG, Younathan ES, Chang SH. Human 6-phosphofructo-1-kinase gene has an additional intron upstream of start codon. Gene 76(1):167-9, 3/1989. PMID: 2526044.
5. Fonagy A, Henning D, Jhiang S, Haidar M, Busch RK, Larson R, **Valdez B**, Busch H. Cloning of the cDNA and sequence of the human proliferating-cell nucleolar protein P120. Cancer Commun 1(4):243-51, 1989. PMID: 2576976.
6. **Valdez BC**, Busch RK, Larson RG, Busch H. Identification of an epitope region of the human proliferation-associated nucleolar antigen P120. Cancer Res 50(9):2704-7, 5/1990. PMID: 1691680.

7. Busch, H, Busch, RK, Freeman, JW, Larson, R, Haidar, M, Jhiang, S, **Valdez, BC**and Zhang, WW. Biotechnology and human tumor nucleolar antigens. Nuclear Structure and Function, J.R. Harris and I.B. Zbarsky (Eds.) Plenum Press, New York:237-242, 8/1990.
8. **Valdez BC**, Busch RK, Busch H. Phosphorylation of the human cell proliferation-associated nucleolar protein p120. Biochem Biophys Res Commun 173(1):423-30, 11/1990. PMID: 2256932.
9. Freeman, JW, Busch, RK, Fonagy, A, McGrath, P, Perlaky, L, **Valdez, B**and Busch, H. Regulation of proliferation-associated nucleolar antigen p120 expression: Relation to oncogenesis. Clinical Biotech 3:223-229, 6/1991.
10. Perlaky L, **Valdez BC**, Busch RK, Larson RG, Jhiang SM, Zhang WW, Brattain M, Busch H. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res 52(2):428-36, 1/1992. PMID: 1728415.
11. **Valdez BC**, Perlaky L, Saijo Y, Henning D, Zhu C, Busch RK, Zhang WW, Busch H. A region of antisense RNA from human p120 cDNA with high homology to mouse p120 cDNA inhibits NIH 3T3 proliferation. Cancer Res 52(20):5681-6, 10/1992. PMID: 1394192.
12. Saijo Y, Perlaky L, **Valdez BC**, Busch RK, Henning D, Zhang WW, Busch H. The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett 68(2-3):95-104, 2/1993. PMID: 8443798.
13. Saijo Y, Perlaky L, **Valdez BC**, Wang H, Henning D, Busch H. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466. Oncol Res 5(8):283-91, 1993. PMID: 8012060.
14. **Valdez BC**, Perlaky L, Henning D, Saijo Y, Chan PK, Busch H. Identification of the nuclear and nucleolar localization signals of the protein p120. Interaction with translocation protein B23. J Biol Chem 269(38):23776-83, 9/1994. PMID: 8089149.
15. Busch RK, Perlaky L, **Valdez BC**, Henning D, Busch H. Apoptosis in human tumor cells following treatment with p120 antisense oligodeoxynucleotide ISIS 3466. Cancer Lett 86(2):151-7, 11/1994. PMID: 7982202.
16. **Valdez BC**, Henning D, Le TV, Busch H. Specific aspartic acid-rich sequences are responsible for silver staining of nucleolar proteins. Biochem Biophys Res Commun 207(2):485-91, 2/1995. PMID: 7532402.
17. Weidner DA, **Valdez BC**, Henning D, Greenberg S, Busch H. Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett 366(2-3):146-50, 6/1995. PMID: 7789533.
18. **Valdez BC**, Henning D, Busch RK, Srivastava M, Busch H. Immunodominant RNA recognition motifs of human nucleolin/C23. Mol Immunol 32(16):1207-13, 11/1995. PMID: 8559145.
19. Durban E, **Valdez BC**, Gustafson WC, Taylor CW, Cardellini E, Busch H. Functional domains of nucleolar phosphoprotein p120. Physiol Chem Phys Med NMR 27(4):303-11, 1995. PMID: 8768786.
20. Ren Y, Busch R, Durban E, Taylor C, Gustafson WC, **Valdez B**, Li YP, Smetana K, Busch H. Overexpression of human nucleolar proteins in insect cells: Characterization of nucleolar protein p120. Protein Expr Purif 7(2):212-219, 3/1996. PMID: 8812864.
21. **Valdez BC**, Henning D, Busch RK, Woods K, Flores-Rozas H, Hurwitz J, Perlaky L, Busch H. A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Nucleic Acids Res 24(7):1220-4, 4/1996. PMCID: PMC145780.
22. Li YP, Busch RK, **Valdez BC**, Busch H. C23 interacts with B23, a putative nucleolar-localization-signal-binding protein. Eur J Biochem 237(1):153-8, 4/1996. PMID: 8620867.
23. **Valdez BC**, Henning D, Perlaky L, Busch RK, Busch H. Cloning and characterization of Gu/RH-II binding protein. Biochem Biophys Res Commun 234(2):335-40, 5/1997. PMID: 9177271.
24. Arnett FC, Reveille JD, **Valdez BC**. Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum 40(8):1487-92, 8/1997. PMID: 9259430.

25. Zhu L, Perlaky L, Henning D, **Valdez BC**. Cloning and characterization of a new silver-stainable protein SSP29, a member of the LRR family. Biochem Mol Biol Int 42(5):927-35, 8/1997. PMID: 9285060.
26. Perlaky L, **Valdez BC**, Busch H. Effects of cytotoxic drugs on translocation of nucleolar RNA helicase RH-II/Gu. Exp Cell Res 235(2):413-20, 9/1997. PMID: 9299166.
27. **Valdez BC,** Henning D, Perumal K, Busch H. RNA-unwinding and RNA-folding activities of RNA helicase II/Gu--two activities in separate domains of the same protein. Eur J Biochem 250(3):800-7, 12/1997. PMID: 9461305.
28. **Valdez, BC**, Henning, D, Zhu, L, Stetler, DA. Silver (Ag-NOR) staining of nucleolar transcription factor UBF requires adjacent aspartic acid residues. J. Histotech 21:13-18, 3/1998.
29. Gustafson WC, Taylor CW, **Valdez BC**, Henning D, Phippard A, Ren Y, Busch H, Durban E. Nucleolar protein p120 contains an arginine-rich domain that binds to ribosomal RNA. Biochem J 331 (Pt 2):387-93, 4/1998. PMID: 9531475.
30. **Valdez BC**, Perlaky L, Cai ZJ, Henning D, Busch H. Green fluorescent protein tag for studies of drug-induced translocation of nucleolar protein RH-II/Gu. Biotechniques 24(6):1032-6, 6/1998. PMID: 9631199.
31. Ou Y, Fritzler MJ, **Valdez BC**, Rattner JB. Mapping and characterization of the functional domains of the nucleolar protein RNA helicase II/Gu. Exp Cell Res 247(2):389-98, 3/1999. PMID: 10066367.
32. Zhu K, Henning D, Iwakuma T, **Valdez BC**, Busch H. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. Biochem Biophys Res Commun 266(2):361-5, 12/1999. PMID: 10600508.
33. Garcia MC, Zhou J, Henning D, Arnett FC, **Valdez BC**. Unique epitopes in RNA helicase II/Gu protein recognized by serum from a watermelon stomach patient. Mol Immunol 37(7):351-9, 5/2000. PMID: 11074253.
34. **Valdez BC**, Wang W. Mouse RNA helicase II/Gu: cDNA and genomic sequences, chromosomal localization, and regulation of expression. Genomics 66(2):184-94, 6/2000. PMID: 10860663.
35. **Valdez BC**. Structural domains involved in the RNA folding activity of RNA helicase II/Gu protein. Eur J Biochem 267(21):6395-402, 11/2000. PMID: 11029582.
36. Henning D, **Valdez BC**. Expression of p40/Epstein-Barr virus nuclear antigen 1 binding protein 2. Biochem Biophys Res Commun 283(2):430-6, 5/2001. PMID: 11327720.
37. Coccia EM, Stellacci E, Orsatti R, Benedetti E, Giacomini E, Marziali G, **Valdez BC**, Battistini A. Protein inhibitor of activated signal transducer and activator of transcription (STAT)-1 (PIAS-1) regulates the IFN-gamma response in macrophage cell lines. Cell Signal 14(6):537-45, 6/2001. PMID: 11897494.
38. Izumi RE, **Valdez B**, Banerjee R, Srivastava M, Dasgupta A. Nucleolin stimulates viral internal ribosome entry site-mediated translation. Virus Res 76(1):17-29, 7/2001. PMID: 11376843.
39. **Valdez BC**, Yang H, Hong E, Sequitin AM. Genomic structure of newly identified paralogue of RNA helicase II/Gu: detection of pseudogenes and multiple alternatively spliced mRNAs. Gene 284(1-2):53-61, 2/2002. PMID: 11891046.
40. Westermarck J, Weiss C, Saffrich R, Kast J, Musti AM, Wessely M, Ansorge W, Seraphin B, Wilm M, **Valdez BC**, Bohmann D. The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription. Embo J 21(3):451-60, 2/2002. PMID: 11823437.
41. **Valdez, BC**, Perlaky, L, Henning, D. A new paralogue of RNA helicase II/Gu localizes to nucleoli and splicing factor-containing nuclear speckles. Expt. Cell Research 276:249-263, 11/2002.
42. Yang H, Zhou J, Ochs RL, Henning D, Jin R, **Valdez BC**. Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte. J Biol Chem 278(40):38847-59, 10/2003. PMID: 12851405.
43. Henning D, So RB, Jin R, Lau LF, **Valdez BC**. Silencing of RNA helicase II/Gualpha inhibits mammalian ribosomal RNA production. J Biol Chem 278(52):52307-14, 12/2003. PMID: 14559904.

44. So RB, Gonzales B, Henning D, Dixon J, Dixon MJ, **Valdez BC**. Another face of the Treacher Collins syndrome (TCOF1) gene: identification of additional exons. Gene 328:49-57, 3/2004. PMID: 15019983.
45. **Valdez BC**, Henning D, So RB, Dixon J, Dixon MJ. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor (UBF). Proc Natl Acad Sci U S A 101(29):10709-14, 7/2004. PMID: 15249688.
46. Gonzales B, Henning D, So RB, Dixon J, Dixon MJ, **Valdez BC**. The Treacher Collins syndrome (TCOF1) gene product is involved in methylation of ribosomal RNA. Hum Mol Genet 14(14):2035-43, 7/2005. PMID: 15930015.
47. Yang H, Henning D, **Valdez BC**. Functional interaction between RNA helicase II/Gu(alpha) and ribosomal protein L4. FEBS J 272(15):3788-802, 8/2005. PMID: 16045751.
48. Gonzales B, Yang H, Henning D, **Valdez BC**. Cloning and functional characterization of the Xenopus orthologue of the Treacher Collins syndrome (TCOF1) gene product. Gene 359:73-80, 10/2005. PMID: 16125876.
49. Holmström TH, Mialon A, Kallio M, Nymalm Y, Mannermaa L, Holm T, Johansson H, Black E, Gillespie D, Salminen TA, Langel U, **Valdez BC**, Westermarck J. c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21. J Biol Chem 283(11):7046-53, 3/2008. e-Pub 1/2008. PMID: 18180292.
50. **Valdez BC**, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32(11):1687-1697, 11/2008. e-Pub 3/2008. PMCID: PMC2633244.
51. **Valdez BC**, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364-72, 3/2010. e-Pub 9/2009. PMCID: PMC2823987.
52. **Valdez BC**, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen 51(6):659-68, 7/2010. PMCID: PMC4346159.
53. **Valdez BC**, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 81(2):222-32, 1/2011. e-Pub 10/2010. PMCID: PMC3006064.
54. Andersson BS, **Valdez BC**, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 6/2011. e-Pub 10/2010. PMCID: PMC3760472.
55. **Valdez BC**, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leuk Lymphoma 53(5):973-81, 5/2012. e-Pub 12/2011. PMCID: PMC3867126.
56. Nieto Y, Thall P, **Valdez B**, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 11/2012. e-Pub 5/2012. PMCID: PMC4010147.
57. **Valdez BC**, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 40(10):800-10, 10/2012. e-Pub 6/2012. PMCID: PMC3447105.
58. Nieto Y, Popat U, Anderlini P, **Valdez B**, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on

Outcome. Biol Blood Marrow Transplant 19(3):410-7, 3/2013. e-Pub 11/2012. PMCID: PMC4077191.

59. **Valdez BC**, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 8/2013. e-Pub 5/2013. PMCID: PMC3769691.
60. Song G, **Valdez BC**, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma 55(7):1625-1634, 7/2014. e-Pub 2/2014. PMCID: PMC4320642.
61. **Valdez BC**, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J 4:e171, 1/2014. e-Pub 1/2014. PMCID: PMC3913938.
62. Song G, **Valdez BC**, Li Y, Liu Y, Champlin RE, Andersson BS. Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leukemia Cells. Biol Blood Marrow Transplant 20(11):1687-1695, 11/2014. e-Pub 8/2014. PMID: 25111583.
63. **Valdez BC**, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: enhancement of cytotoxicity with epigenetic modulators. Exp Hematol 43(6):448-461, 6/2015. e-Pub 2/2015. PMID: 25704054.
64. Nieto Y, **Valdez BC**, Thall P, Jones RB, Ahmed S, Hosing C, Shpall EJ, Qazilbash M,Anderlini P,Shah N, Bashir Q, Popat U, Alousi A, Chancoco C, Worth L, Fox P, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory or Poor-Risk Relapsed Lymphomas. Biol Blood Marrow Transplant. e-Pub 6/2015.
65. **Valdez BC**, Brammer JE,Yang L, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin Targets Multiple Survival Signaling Pathways in Malignant T-cells. Blood Cancer Journal, 10/2015. e-Pub 10/2015.
66. Teo EC, **Valdez BC**, Ji J, Li Y, Liu Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat and bortezomib in lymphoma cells. Leukemia and Lymphoma 57(11):2644-2652, 3/2016.
67. **Valdez BC**, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research 47:100-108, 5/2016.
68. Ji J, **Valdez BC**, Yang L, Yan L, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan and SAHA combination as a potential pre-transplant conditioning regimen for lymphomas: a preclinical study. Exptl Hemat. 44(6):458-465, 6/2016.
69. Nieto Y, **Valdez BC**, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. DOUBLE EPIGENETIC MODULATION OF HIGH-DOSE CHEMOTHERAPY WITH AZACITIDINE AND VORINOSTAT FOR PATIENTS WITH REFRACTORY OR POOR-RISK RELAPSED LYMPHOMA. Cancer 122(17):2680-2688, 9/2016. e-Pub 5/2016. PMCID: PMC4992444.
70. Andersson BS, Thall PF, **Valdez BC**, et al. Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 4/2017.
71. Nieto Y, **Valdez BC**, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 11/2015. e-Pub 6/2015. PMCID: PMC4781754.

72. Andersson BS, **Valdez BC**. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? Bone Marrow Transplant. e-Pub 4/2016. PMID: 27111045.
73. Alatrash G, Thall PF, **Valdez BC**, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant. e-Pub 7/2016. PMID: 27377901.
74. **Valdez BC**, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget 7(39):63829-63838, 8/2016.
75. **Valdez BC**, Perlaky L, Henning D. Expression, cellular localization, and enzymatic activities of RNA helicase II/Gu(beta). Exp Cell Res 276(2):249-63, 6/2002. PMID: 12027455.
76. **Valdez BC**, Perlaky L. Drug-induced translocation of nucleolar proteins fused to green fluorescent protein. Methods Mol Biol 183:151-61, 2002. PMID: 12136750.
77. Song G, Banov D, Bassani AS, **Valdez BC**. Evaluation of the Safety, Cell Migration, and Mucoadhesive Properties of a Mucoadhesive Polymer Blend in Human Oral Mucosa. AAPS PharmSciTech 18(5):1617-1623, 7/2017.
78. Kebriaei P, Bassett R, Lyons G, **Valdez B**, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2/2017. e-Pub 11/2016. PMID: 27816651.
79. **Valdez BC**, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma: 2017;58:2705-2716. PMID: 28394191.
80. **Valdez BC**, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017;52:65-71. PMID: 28479418.
81. Nieto Y, **Valdez BC,** Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematology, 2017:4:e283-e292.
82. **Valdez BC**, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2017. 17;9:3908-3921.
83. Nieto Y, Thall PF, Ma J, **Valdez BC**, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 Mar 2. pii: S1083-8791(18)30106-X. doi: 10.1016/j.bbmt.2018.02.020. [Epub ahead of print]

Invited Articles

1. Valdez, BC, Perlaky, L, Cai, Z-J, Henning, D, Busch, H. Green fluorescent protein tag for studies of drug-induced translocation of nucleolar protein RH-II/Gu. Expression Genetics: Accelerated and High-throughput Methods (Ed. M. McClelland and A. B. Pardee) Eaton Publishing:321-328, 3/1999.

Editorials

N/A

Other Articles

N/A

Abstracts

1. Valdez BC, Wang G, Murray Y, NietoY, Li Y, Qazilbash MH, Champlin RE, and Andersson BS. Mechanistic Studies of the Synergistic Cytotoxicity of Clofarabine and Gemcitabine in Multiple Myeloma Cell Lines: Relevance of p53-status. 2013 BMT Tandem Meetings, Salt Lake City, Utah 19(2):S239-S240, 2/2013.
2. Wang G, Valdez BC, Li Y, Dominguez JR, Champlin RE, and Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. 2013 BMT Tandem Meetings, Salt Lake City, UT #236, 2/2013.
3. Valdez BC, Song G, Murray D, Nieto Y, Li Y, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. 18 Annual European Hematology Conference in Stockholm Sweden, 2013.
4. Valdez BC, Zander AR, Li Y, Song G, Andersson BS. Synergistic cytotoxicity of edelfosine, gemcitabine and clofarabine in t-cell lymphoma. 18 Annual European Hematology Association Conference in Stockholm, Sweden, 2013.
5. Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine (± DNA alkylating agent) in lymphoma cell lines. American Society For Blood and Marrow Transplantation Annual Meeting 2014, 2/2014.
6. Song G, Valdez BC, Li, Y, Liu Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of the multikinase inhibitor sorafenib with the DNA alkylating agent busulfan, and nucleoside analogs in human FLT3-ITD-positive acute myeloid leukemia cell lines. American Society for Bone and Marrow Transplantation Annual Meeting 2014, 2/2014.
7. Chu D, Valdez BC, Fox P, Thall BF, Worth LL, Popat U, Jones RB et al. Clofarabine ± Fludarabine with IV Busulfan and allogeneic stem cell transplantation for advanced myeloid leukemia (ML) and MDS. American Society for Bone and Marrow Transplantation Annual Meeting 2014, 2/2014.
8. Nieto Y, Thall PF, Valdez BC et al. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. ASH Annual Meeting 2013 (#2095), 2013.
9. Nieto Y, Shah N, Popat U, et al. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. ASH Annual Meeting 2013 (#3346), 2013.
10. Muzaffar H. Qazilbash, Peter F. Thall, Patricia S Fox, Partow Kebriaei, Qaiser Bashir, Nina Shah, Krina Patel, Borje Andersson, Yago Nieto, Ben Valdez, Simrit Parmar, Gabriela Rondon, Ruby Delgado, Yvonne Dinh, Chitra Hosing, Uday R. Popat, Jatin J. Shah, Robert Z. Orlowski, Richard E. Champlin. Promising Progression-Free Survival Despite Early Termination In A Randomized Phase III Trial Of Busulfan + Melphalan Vs Melphalan Alone For Multiple Myeloma. American Society of Hematology 2014. e-Pub 11/2014.
11. Uday Popat, Patricia Fox, Roland Bassett, Julianne Chen, Ben Valdez, Jitesh Kawedia, Sairah Ahmed, Amin M. Alousi, Qaiser Bashier, Stefan Ciurea, Chitra Hosing, Roy Jones, Partow Kebriaei, Issa Khouri, Yago Nieto, Amanda Olson, Betul Oran, Muzaffar H. Qazilbash, Nina Shah, E. J. Shpall, Borje S. Andersson, Richard Champlin. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. American Society of Hematology 2014. e-Pub 11/2014.
12. Qazilbash MH, Kebriaei P; Nieto Y; Andersson BS, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Valdez BC, Shah J, Orlowski R, Champlin RE, Dinh YT. Randomized Phase III Trial

of Busulfan + Melphalan Vs. Melphalan Alone for Multiple Myeloma. American Society of Clinical Oncology 2014. e-Pub 5/2014.

13. Yago Nieto, Uday Popat, Paolo Anderlini, Chitra Hosing, Borje S Andersson, Ben Valdez, Elizabeth J Shpall, Sairah Ahmed, Muzaffar Qazilbash, Roland Bassett, Partow Kebriaei, Amin Alousi, Priti Tewari, Laura Worth, Richard Champlin, Roy B Jones. GEMCITABINE/BUSULFAN/MELPHALAN IS A SAFE AND EFFECTIVE HIGH-DOSE CHEMOTHERAPY REGIMEN FOR REFRACTORY OR POOR-RISK RELAPSED HODGKIN'S LYMPHOMA: RESULTS OF A PROSPECTIVE PHASE 2 TRIAL. European Bone Marrow Transplant Meeting 2014. e-Pub 2/2014.
14. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: enhancement of cytotoxicity with epigenetic modulators. ASBMT Tandem Meeting 2015 (#251), 2/2015.
15. Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes lymphoma cells to combination of cladribine and gemcitabine with DNA alkylating agent busulfan. ASBMT Tandem Meeting 2015, 2/2015.
16. McCurdy SH, Vulic A, Symons JJ, Towlerton AM, Valdez BC, Jones RJ, Fuchs EJ, O'Donnell PV, Warren EH, Kanakry CG, Luznik L. Comparable and Robust Immune Reconstitution after HLA-Haploidentical or HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide. ASBMT Tandem Meeting 2015, 2/2015.
17. Nieto Y, Valdez BC, et al. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. ASH 2015, 12/2015.
18. Nieto Y, Bassett R, Anderlini P, Hosing C, Amin A, Popat U, Andersson BS, Valdez BC et al. PROSPECTIVE PHASE 2 TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN (GEM/BU/MEL) WITH AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) WITHOUT POST-ASCT MAINTENANCE, IN HODGKIN'S LYMPHOMA PATIENTS AT HIGH RISK OF POSTTRANSPLANT RECURRENCE – COMPARISON WITH A CONCURRENT COHORT TREATED WITH BEAM. ASH 2015, 12/2015.
19. Popat U, Lyons G, Bassett R, Chen, J, Valdez BC et al. Myeloablative Timed Sequential Busulfan Is Safe and Appears Promising in Older Patients with AML/MDS. ASH 2015, 12/2015.
20. Popat U, Lyons, G, Bassett R, Poon MYC, Valdez B, et al. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. ASH 2015, 12/2015. e-Pub .
21. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. ASBMT Annual Meeting 2016. In Press.
22. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. EBMT Annual Meeting 2016. In Press.
23. Nieto Y, Milton D, Pingali R, Shah N, Jones RB Valdez BC et al. MATCHED PAIR COMPARISON OF CONCURRENT COHORTS OF PATIENTS WITH RELAPSED/REFRACTORY (R/R) MYELOMA RECEIVING AN AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) TRANSPLANTED WITH GEMCITABINE/BUSULFAN/MELPHALAN OR MELPHALAN. EBMT Annual Meeting 2016. In Press.

Book Chapters

1. Valdez BC, Perlaky L. Drug-Induced Translocation of Nucleolar Proteins F used to Green Fluorescent Protein in Methods in Molecular Biology, Green Fluorescent Protein Applications and Protocols. In: Methods in Molecular Biology. 183. Ed(s) BW Hicks, 151-162, 2002.
2. Andersson BS, Valdez BC, Jones R. Pharmacologic Basis for High-dose Chemotherapy. In: Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fifth. Ed(s) SJ Forman, RS Negrin, JH Antin, FR Appelbaum. John Wiley & Sons, Ltd: NJ, USA, 211-222, 2016. PMID: 978-1-118-41600-6.

Books (edited and written)
N/A

Letters to the Editor
N/A

Manuals, Teaching Aids, Other Teaching Publications
N/A

Other Publications
N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)
N/A

Member of Editorial Review Board
Editorial Board, Journal of Stem Cell Research and Therapy, 2010-present

Member of Editorial Board, Chemotherapy: Open Access, 2011-present

Member, International Journal of Stem Cell Research and Transplantation, 2012-present

Journal Reviewer
Reviewer, Genomics, 2000-2001

Reviewer, Nucleic Acids Research, 2000-2001

Reviewer, Cancer Research, 2000-present

Reviewer, Cancer Letters, 2001-2004

Reviewer, BBA, 2003-present

Reviewer, Molecular and Cellular Biology, 2004

Reviewer, Human Mutations, 2004-2005

Reviewer, Clinical Cancer Research, 2006-present

Reviewer, Molecular Cancer Therapy, 2006-present

Reviewer, Proceedings of the National Academy of Sciences, USA, 2006-present

Reviewer, Journal of Cellular and Molecular Medicine, 2007-present

Reviewer, Nature Medicine, 2007-present

Reviewer, Annals of Human Genetics, 2008

Reviewer, International J of Biochem and Cellular Biol, 2008

Reviewer, Molecular Cancer Research, 2008

Reviewer, Indian Journal of Ophthalmology, 2009

Reviewer, Ann Human Genetics, 2009-present

Reviewer, Human Molecular Genetics, 2009-present

Reviewer, J of Cell and Molecular Medicine, 2009-present

Reviewer, Neoplasia, 2009-present

Reviewer, PLoS Genetics, 2011-present

Reviewer, Archives of Medicine, 2012-present

Reviewer, Biochemical Pharmacology, 2012-present

Reviewer, Current Drug Safety, 2012-present

Reviewer, JAMS, 2012-present

Reviewer, Leukemia Research, 2012-present

Reviewer, Life Sciences, 2012-present

Reviewer, Science, 2012-present

Reviewer, World Journal of Surgical Oncology, 2012-present

REviewer, Chemotherapy, 2013-present

Reviewer, International Journal of Molecular Science, 2013-present

Reviewer, J of Hematology and Oncology, 2013-present

Other Editorial and Review Activities

Reviewer, n/a, Nature Medicine, Proceedings of the National Acad of Sciences USA, Molecular and Cellular Biology, Cancer Research, Nucleic Acids Research, Cancer Letters, Genomics, Clinical Cancer Research, Human Mutations, BBA, John Wiley and Sons, Inc., 1996

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

Research Mentor, Summer Student training program, Jose Dominguez, Contact Hours: 8 hrs/day, 6/2011-7/2011

Research Mentor, Undergraduate Summer Program, Jose Dominguez, Contact Hours: 8 hrs, 6/2012-7/2012

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

Yang Li, MS, 2007-present

Guiyun Wang, PhD, 2009-present

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Instructor, GI drugs, Baylor College of Medicine
1999-2004

Instructor, Pharmacokinetics, Baylor College of Medicine
1999-2004

Instructor, Renal drugs, Baylor College of Medicine
1999-2004

Instructor, Respiratory drugs, Baylor College of Medicine
1999-2004

Instructor, Pharmacokinetics, Baylor College of Medicine
2001-2003

General Principles of Pharmacology module, Baylor College of Medicine
2003-2005

Instructor, Pharmacokinetics, Baylor College of Medicine
2003-2005

Training Programs

N/A

Other Formal Teaching

Lecturer, Genetic Basis of Diseases, St. Vincent de Paul School, Course Number: Grade 7 Science
2004-2007

Supervisory Teaching

Committees

Advisory Committees

Member, Advisory and examining comm, Baylor Coll of Med, Eugene Hong, PhD, 2000-2006

Member, Thesis and examining comm, Baylor Coll Med, David Bloom, PhD

Member, thesis and examining comm, Baylor Coll Med, Delwin Long, PhD

Member, thesis and examining comm, Baylor Coll Med, Jian Gu, PhD

Member, thesis and examining comm, Baylor Coll Med, Karim Iskander, PhD

Member, thesis and examining comm, Baylor Coll of Med, Kartika Perumal, PhD

Member, thesis and examining comm, Baylor Coll Med, Rick Finch, PhD

Member, thesis and examining comm, Baylor Coll of Med, Wei Wang, PhD

Member, thesis and examining comm, Baylor Coll Med, Yahua Chen, PhD

Member, thesis and examining comm, Baylor Coll of Medicine, Zhi-Qi Xiong, PhD

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

Research Mentor, Summer Research Program, Baylor College of Med, Mary Catherine Garcia, 1999

Research Mentor, Summer Research Program, Baylor Coll Med, Rocio Benabentos, 2004

Medical Students
N/A

Graduate Students
Committee Chair, Baylor Coll of Med, Hushan Yang, PhD, 1999-2005

Committe Chair, Baylor College of Med, Bianca Gonzales, MS, 2003-2005

Postdoctoral Research Fellows
Research Mentor, Baylor College of Medicine, Liangjin Zhu, Ph.D., 1996-1997

Research Mentor, Baylor College of Medicine, Feng Yang, Ph.D., 1999-2000

Research Mentor, Baylor College of Medicine, Juhua Zhou, Ph.D., 1999-2000

Clinical Residents and Fellows
N/A

Other Supervisory Teaching
N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)
N/A

Presentations at National or International Conferences

Invited

Valdez BC. Combination of DNA Crosslinking Agents and Nucleoside Analouges in the Treatment of Leukemia, BIT, Singapore, 6/23/2010

Valdez BC. Combinatory drug regimen for treatment of hematologic malignancies, China Medical Biotech Forum, Beijing, China, 11/7/2011

Valdez BC, Andersson BS. Targeting Histone Modifications to Enhance Drug Efficacy in Hematopoietic Stem Cell Transplantation, BIT Conferences, Inc, Suzhou, China, 3/2013

Valdez BC. Efficacy of nucleoside analogs, DNA alkylators and epigenetic modifiers in hematopoietic stem cell transplantation, Scientific Future Group, Dubai, United Arab Emirates, 8/27/2015

Valdez BC. Pre-transplant regimen and immunomodulation in hematopoietic stem cell transplantation, Ludong University, Ludong University, Yantai, Shandong, China, 9/20/2015

Valdez BC. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. EBMT Annual Meeting 2016, Valencia, Spain

Valdez BC. Targeting DNA repair to treat hematological malignancies, BIT Congress, Macau, Macau, 11/13/2017

Valdez BC. Mechanism-based optimization of conditioning regimen for stem cell transplantation in lymphoma. World Academy of Sciences, Bangkok, Thailand, April 12-15, 2018

Other, Including Scientific Exhibitions
Valdez BC. 15th International Workshop on the Cell Nucleus, Wilhelm Bernard Workshop Organizer, Quebec, Canada, 2/15/1998

Valdez BC, Nieto Y, Murray D , Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic Changes Enhance The Cytotoxicity Of Combined Nucleoside Analog-Dna Alkylating Agents In Lymphoma Cells, 2012 ASBMT Tandem Meetings, San Diego, CA, 2/1/2012

Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Histone modifications and DNA demethylation enhance the cytotoxicity of combined nucleoside analog-DNA alkylating agents in human lymphoma cell lines, European Bone Marrow Transplant, Geneva, Switzerland, 4/2/2012

Combinatory Drug Regimen for Hematopoietic Stem Cell Transplantation, International Drug Discovery Science and Technology, Nanjing, China, 11/8/2012

Valdez BC, Brammer J, Li Y, Murray D, Teo E, Liu Y, Hosing C, Nieto Y, Champlin R, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan in malignant T-cells, European Bone Marrow Transplant, Valencia, Spain, 4/4/2016

Valdez BC, Li Y, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy, SINGHEALTH-DUKE-NUS, Singapore, Singapore, 9/23/2016

Valdez BC, Li Y, Andersson BS. Importance of understanding the mechanisms of action of drugs used in combination chemotherapy, Academicfora, Manila, Philippines, 9/28/2016

Seminar Invitations from Other Institutions

Characterization of nucleolar proteins p120 and B23, their physical interactions and nucleolar localization, Biochemistry Graduate Student Council, Louisiana State Univ, Biochemistry, Baton Rouge, LA, 8/12/1994

Localization and interactions of nucleolar proteins, Ohio State Univ, Physiology, Columbus, OH, 10/3/1994

A nucleolar RNA helicase: Characterization of an autoimmune antigen, Baylor Coll Medicine, Pharmacology, Houston, TX, 4/19/1996

Identification of mutations in the TCOF1 gene of two related patients diagnosed with Treacher Collins syndrome., Annual Biomedical Research Conference for Minority Students (ABRCMS), ABRCMS, Dallas, TX, 11/10/2004

Treacher Collins Syndrome (TCOF1) gene product: functional analyses in craniofacial development, Coriell Institute for Medical Research, Camden, NJ, 3/7/2005

Synergistic cytotoxicity of pre-transplant drugs used in hematopoietic stem cell transplantation, Millipore, Millipore Webinar (on line), 10/2/2013

Lectureships and Visiting Professorships

N/A

Other Presentations at State and Local Conferences

Valdez BC. IV Busulfan in Stem Cell Transplantation: Translational Studies, Dept Seminar Series, UT MDACC, SCT&CT, Houston, TX, 9/13/2007

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Society of Hematology
Active Member, 2006-present

Local/State

N/A

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

11/28/2017